Articles related to Surgery, General

In addition to reducing pack-years history of smoking, the recommendation calls for annual screening for lung cancer at age 50 years instead of age 55 years, an update of the U.S. Preventive Services Task Force (USPSTF) guidance on lung cancer screening issued 7 years ago.

In this podcast, Dr. Jennifer Caudle speaks with Drs. Kathryn Ruddy and Joerg Herrmann from the cardio-oncology clinic at the Mayo Clinic to talk about the field that’s devoted to improving cardiovascular health both during and after cancer therapy.

In this podcast from the virtual 2020 ESMO World Congress on Gastrointestinal Cancer, Dr. Zev Wainberg discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC).

Published on the AUA website and developed by a panel of experts from these three groups as well as representation from the American Society of Clinical Oncology (ASCO) and a patient advocate, 38 recommendations are listed across the care continuum of advanced disease.

According to the FDA, Phesgo — the combination of pertuzumab, trastuzumab and hyaluronidase-zzxf – is initially used in combination with chemotherapy and then can be administered subcutaneously at home by a health care professional after completion of chemotherapy.

This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo.